After a mixed few years for shareholders, TransMedics Group stock now sits at around US$76 with a 5 year return of roughly 154%, and the current valuation checks suggest that, despite recent share price pressure, the stock still leans toward the cheaper side of the spectrum.

• Over 5 years, TransMedics Group has returned about 153.6%, which puts the recent 1 year and year to date share price declines in the context of a much stronger longer term run.
• The recent investment in Germany based PAD Aviation can support expectations that TransMedics Group may scale its organ transplant logistics platform in Europe, while execution risk around integrating and ramping this network may weigh on how investors price the stock.
• On Simply Wall St's broader checks, TransMedics Group screens as attractively valued in 5 of 6 measures, which means the overall score of 5 out of 6 leans toward the company looking undervalued rather than expensive.

The stock's next move may depend on whether the market continues to focus on the recent price weakness or on the indication from the valuation checks that TransMedics Group could still be pricing in relatively modest expectations.

Does TransMedics Group Look Undervalued on Earnings?

The P/E ratio is a useful way to judge how much investors are paying for each dollar of TransMedics Group’s earnings. Right now, TransMedics Group trades on a P/E of about 15.3x, which is well below the Medical Equipment industry average of roughly 27.5x and also below the peer group average of about 44.4x.

On Simply Wall St’s model, a P/E of around 24.5x would be more in line with what you might expect for TransMedics Group given its profile. The current 15.3x reading therefore sits materially under that fair ratio. Despite the recent PAD Aviation deal in Europe catching investor attention, the stock price still implies a lower earnings multiple than both the tailored fair ratio and the sector benchmarks.

Overall, the current P/E suggests TransMedics Group stock appears undervalued on this earnings multiple.

The TransMedics Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the TransMedics Group valuation puzzle leaves off by spelling out what kind of future growth, margins and earnings would need to play out for the stock to be worth materially more or less than it is today. Each Narrative links a specific set of catalysts and risks to its own fair value view for TransMedics Group, so you can see over time which underlying story appears to be taking shape.

One of the top community narratives on TransMedics Group: 36% undervalued

"Development of a recurring, service-driven revenue model, including logistics, digital ecosystem, and service contracts, enables more predictable and stable cash flows..."

Do you think there's more to the story for TransMedics Group? Head over to our Community to see what others are saying!

The Bottom Line

For investors looking at TransMedics Group today, the main message from the valuation work is that the stock still screens as undervalued on earnings multiples relative to peers and tailored benchmarks. The key question is whether that discount reflects lingering concern about execution risk as the business integrates assets like PAD Aviation and builds out its logistics platform, or whether the market is simply slow to re-rate the stock. From here, the crux of the debate is whether TransMedics Group can deliver on its operating plans in a way that convinces investors to close that valuation gap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.